Contrasting CNS Pharmaceuticals (NASDAQ:CNSP) & Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Valuation and Earnings

This table compares Dyadic International and CNS Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.42 million	10.63	-$5.81 million	($0.19)	-5.29
CNS Pharmaceuticals	N/A	N/A	-$14.86 million	($175.45)	-0.04

Dyadic International has higher revenue and earnings than CNS Pharmaceuticals. Dyadic International is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Dyadic International has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, CNS Pharmaceuticals has a beta of 2.7, meaning that its stock price is 170% more volatile than the S&P 500.

Institutional & Insider Ownership

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 29.5% of Dyadic International shares are held by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Dyadic International and CNS Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyadic International	-134.84%	-355.39%	-60.66%
CNS Pharmaceuticals	N/A	-183.89%	-139.37%

Analyst Ratings

This is a breakdown of recent ratings for Dyadic International and CNS Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1	0	2	0	2.33
CNS Pharmaceuticals	1	0	2	0	2.33

Dyadic International presently has a consensus target price of $3.00, indicating a potential upside of 198.51%. CNS Pharmaceuticals has a consensus target price of $20.00, indicating a potential upside of 198.95%. Given CNS Pharmaceuticals’ higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Dyadic International.

Summary

Dyadic International beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.